SYDNEY, May 17, 2022
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX:
KZA), a late-stage, oncology-focused drug development company,
marks 'DIPG Awareness Day' by recognizing the tireless work of
global researchers in this disease, and by calling for an increased
focus on childhood brain cancer among policymakers.
Brain tumours represent the second most common group of cancers
in children worldwide, after leukemia, but are the most common
cause of cancer death. Around 10-15% of childhood brain cancers are
diffuse midline gliomas (DMGs), a group that includes diffuse
intrinsic pontine glioma (DIPG).
DIPG most commonly affects children between four and eleven
years of age. There is currently no FDA-approved therapy for the
disease, and median survival is just 9 – 11 months from
diagnosis.
Kazia's paxalisib is the subject on an ongoing phase II study in
DIPG and DMGs (NCT05009992), sponsored by the Pacific Pediatric
Neuro-Oncology Consortium (PNOC). Data from the study is
anticipated in CY2023.
New Data to be Presented at ISPNO Conference
The PNOC phase II study has been substantially informed by work
undertaken at the Hunter Medical Research Institute in Newcastle,
Australia, by Associate Professor
Matt Dun and colleagues. Dr Dun is
one of the leading researchers in this disease.
Dr Dun will be presenting new preclinical data describing the
activity of paxalisib in DIPG at the upcoming 20th
International Symposium on Pediatric Neuro-Oncology (ISPNO), which
will be held in Hamburg, Germany,
from 11 to 12 June 2022. Dr Dun's
presentation will specifically cover the combination of paxalisib
with ONC201 (Chimerix, Inc).
Dr Dun commented, "Thirty years ago, children diagnosed with
leukemia only had a 20-30% chance of survival. Thanks to advances
in medicine and a wealth of scientific research, that has now
increased to over 90%. This is the paradigm we want to mirror with
DIPG and I am pleased to report we are currently seeing some very
promising results with our research. We are working tirelessly to
progress the human clinical trials with the aim of being able to
offer new hope to those families with a DIPG diagnosis."
Upcoming Analyst Presentation
Kazia CEO, Dr James Garner, will
participate in an upcoming analyst discussion on childhood brain
cancer, led by Dr Naureen Quibria,
Senior Biotech Analyst at Maxim Group. The panel discussion will
also include Dr Josh Allen, Chief
Medical Officer of Chimerix, Inc, and Dr Sabine Mueller, lead investigator on the PNOC
phase II study of paxalisib and ONC201 in DIPG.
The webinar is scheduled for 9am,
ET, on Thursday 19 May 2022
and interested parties may register to attend the webinar via the
following link:-
https://m-vest.com/events/pediatric-brain-cancer-05192022
DIPG Factsheet Launched
To recognize DIPG Awareness Day, and to encourage awareness and
discussion of the disease, Kazia Therapeutics has supported the
development of a fact sheet, which can be downloaded from the Kazia
website using the following link:-
https://www.kaziatherapeutics.com/site/PDF/c4f1dc99-6874-49ea-af10-cfa3a5a8f39b/KaziaDIPGFactSheet
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-marks-dipg-awareness-day-new-preclinical-data-in-dipg-to-be-presented-at-ispno-conference-301547724.html
SOURCE Kazia Therapeutics Limited